{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:34:18Z","timestamp":1790696058533,"version":"4.1.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"21","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pfizer Inc"},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,9,30]]},"DOI":"10.2217\/fon-2018-0070","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T16:35:01Z","timestamp":1522168501000},"page":"2103-2113","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":67,"title":["Avelumab (Anti-PD-L1) in Platinum-Resistant\/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design"],"prefix":"10.1080","volume":"14","author":[{"given":"Eric","family":"Pujade-Lauraine","sequence":"first","affiliation":[{"name":"\u00a0H\u00f4pital H\u00f4tel-Dieu, Centre des Cancers de la Femme et Recherche Clinique, AP-HP, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Saitama Medical University International Medical Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S","family":"Dychter","sequence":"additional","affiliation":[{"name":"Pfizer Oncology, La Jolla,\u00a0CA92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Devgan","sequence":"additional","affiliation":[{"name":"Pfizer Oncology, New York, NY10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[{"name":"Arizona Oncology (US Oncology Network), University of Arizona & Creighton University, Phoenix, AZ85016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182049273"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw663"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-017-0050-0"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx229"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4037"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.001"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8082"},{"issue":"7","key":"e_1_3_4_14_1","first-page":"CD006910","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","author":"Lawrie TA","year":"2013","unstructured":"Lawrie TA , BryantA, CameronA, GrayE, MorrisonJ. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst. Rev. (7), CD006910 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4240"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.022"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1954-6"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2369"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.03.008"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6429"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-016-0033-6"},{"issue":"12","key":"e_1_3_4_27_1","first-page":"4766","article-title":"Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer","volume":"61","author":"Woo EY","year":"2001","unstructured":"Woo EY , ChuCS, GoletzTJet al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res.61(12), 4766\u20134772 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0654"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.06.014"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.08.004"},{"key":"e_1_3_4_35_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3064","article-title":"Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies","volume":"32","author":"Heery CR","year":"2014","unstructured":"Heery CR , CoyneGHO, MadanRAet al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J. Clin. Oncol.32(Suppl.), Abstract 3064 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30239-5"},{"key":"e_1_3_4_38_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3023","article-title":"Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"33","author":"Shitara K","year":"2015","unstructured":"Shitara K , YamadaY, YohKet al. Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. J. Clin. Oncol.33(Suppl.), Abstract 3023 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30240-1"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6795"},{"key":"e_1_3_4_41_1","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN Solid Tumor Phase Ib trial: analysis of safety and clinical activity","volume":"34","author":"Chung HC","year":"2016","unstructured":"Chung HC , ArkenauH, WyrwiczLet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN Solid Tumor Phase Ib trial: analysis of safety and clinical activity. J. Clin. Oncol.34(Suppl.), Abstract 4009 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_4_42_1","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a Phase Ib JAVELIN solid tumor trial","volume":"76","author":"Dirix LY","year":"2016","unstructured":"Dirix LY , TakacsI, NikolinakosPet al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a Phase Ib JAVELIN solid tumor trial. Cancer Res.76(Suppl. 4), Abstract S1\u201304 (2016).","journal-title":"Cancer Res."},{"issue":"15","key":"e_1_3_4_43_1","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor Phase Ib trial: safety and clinical activity","volume":"34","author":"Disis ML","year":"2016","unstructured":"Disis ML , PatelM, PantSet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor Phase Ib trial: safety and clinical activity. J. Clin. Oncol.34(Suppl. 15), Abstract 5533 (2016).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"e_1_3_4_45_1","unstructured":"Bavencio (avelumab) injection [package insert]. Darmstadt Germany: Merck KGaA; 2017."},{"key":"e_1_3_4_46_1","unstructured":"Bavencio (avelumab) injection [prescribing information (Japan)]. Darmstadt Germany: Merck KGaA; 2017."},{"key":"e_1_3_4_47_1","unstructured":"Bavencio (avelumab) injection [summary of product characteristics]. Darmstadt Germany: Merck KGaA; 2017."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00307-1"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.08.004"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp369"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.012"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:44Z","timestamp":1719125084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":51,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,9,30]]}},"alternative-id":["10.2217\/fon-2018-0070"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0070","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}